Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors
Launched by WASHINGTON UNIVERSITY SCHOOL OF MEDICINE · Oct 13, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The HPARSS trial is a study aimed at improving the way we screen childhood cancer survivors for potential sensory problems, like issues with hearing or vision. Researchers at Washington University School of Medicine are looking to identify young patients who are at risk for these sensory deficits based on the treatments they received. By creating a special document called the HPARSS, they hope to help doctors prompt necessary screenings and follow-up care for these patients, ensuring they receive the support they need.
To join the study, participants must be between 7 and 17 years old, have been diagnosed with cancer before the age of 18, and have completed their cancer treatment (like chemotherapy or radiation) at least 6 months but less than 2 years ago. The study is currently recruiting participants, and it’s important to note that anyone actively undergoing cancer treatment or who has received specific types of therapy for sensory deficits in the past will not be eligible. If you or someone you know fits these criteria, participating in this study could help improve care for childhood cancer survivors by ensuring any sensory issues are identified and managed early.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with a diagnosis of pediatric cancer (diagnosis at \<18 years of age)
- • Treatment including chemotherapy and/or radiation therapy
- • Completion of all cancer therapy for at least 6 months and less than 2 years
- • Followed in the Division of Pediatric Hematology/Oncology Program at the Washington University School of Medicine
- • Current age between 7 and 17 years of age (age where all of the screening tests are both valid and have been successfully performed by our group)
- • English speaking
- Exclusion Criteria:
- • Undergoing active cancer treatment
- • Patient under the care of the Late Effects Program at St. Louis Children's Hospital
- • Received previous diagnostic testing or rehabilitative therapy for a secondary deficit eligible for screening.
- • Parents and/or patient illiteracy
- • No contact with treatment team in the past two years
- • In foster care or without a legal guardian
About Washington University School Of Medicine
Washington University School of Medicine is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research, education, and patient care. With a strong emphasis on translating scientific discoveries into practical applications, the institution conducts a diverse array of clinical trials aimed at improving treatment outcomes and enhancing the understanding of various medical conditions. Its collaborative environment fosters partnerships between researchers, clinicians, and community stakeholders, ensuring that the trials not only contribute to scientific knowledge but also address the pressing health needs of diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Louis, Missouri, United States
Patients applied
Trial Officials
Robert J Hayashi, M.D.
Principal Investigator
Washington University School of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials